28 patents currently held

2 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2031. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Mar 2031

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

202620272028202920302031203220332034 20352036203720382039204020412042204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Controlled Release and Taste Masking Oral Pharmaceutical Composition US 8,895,064

The most cited patent in this portfolio, cited by 38 later US patents, top 25% of utility patents granted in 2014 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.

Ends Sep 2031 · High confidence Also notable

Solid Composition for the Oral Administration of Dyes and Diagnostic Use Thereof US 8,545,811

Cited by 27 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.

Ends Mar 2031 · High confidence Also notable

Emulsions or Microemulsions for Use in Endoscopic Mucosal Resectioning And/Or Endoscopic Submucosal Dissection US 9,226,996

Cited by 18 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.

Ends Nov 2034 · High confidence

Formerly held, still cited

Notable

Systems and Methods for Processing Real-Time Video from a Medical Image Device and Detecting Objects in the Video US 11,100,633

Cited by 34 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2038.

now held by Cosmo Artificial Intelligence - AI Limited

Ends Oct 2038 · High confidence

Also notable

Systems and Methods for Training Generative Adversarial Networks and Use of Trained Generative Adversarial Networks US 10,810,460

The most cited patent in this portfolio, cited by 47 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2038.

now held by Cosmo Artificial Intelligence - AI Limited

Ends Dec 2038 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 4, 2026
The maintenance fee for Controlled Release and Taste Masking Oral Pharmaceutical Composition (US 10,307,375) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
1 fee due Feb 1, 2027
The maintenance fee for 17A-MONOESTERS and 17A,21-Diesters of Cortexolone for Use in the Treatment of Tumors (US 11,712,443) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
2 fees due Mar 15 to 17, 2027 · next Mar 15
1 fee due May 24, 2027
The maintenance fee for Controlled Release and Taste Masking Oral Pharmaceutical Composition (US 9,192,581) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
1 fee due Jul 5, 2027
The maintenance fee for Emulsions or Microemulsions for Use in Endoscopic Mucosal Resectioning And/Or Endoscopic Submucosal Dissection (US 9,226,996) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
1 fee due Nov 12, 2027
The maintenance fee for 17A-MONOESTERS and 17A,21-Diesters of Cortexolone for Use in the Treatment of Tumors (US 10,646,497) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

What they patent

The 5 largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Controlled Release and Taste Masking Oral Pharmaceutical Composition	7 in force	to Sep 2031
Emulsions or Microemulsions for Use in Endoscopic Mucosal Resectioning And/Or Endoscopic Submucosal Dissection	6 in force	to Nov 2034
17A,21-Diesters of Cortexolone for Use in the Treatment of Tumors	5 in force	to Oct 2035
Solid Composition for the Oral Administration of Dyes and Diagnostic Use Thereof	4 in force	to Oct 2031
Oral Rifamycin SV Compositions	2 in force	to Nov 2038

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 8,545,811	Solid Composition for the Oral Administration of Dyes and Diagnostic Use Thereof In force Term ends Mar 2, 2031 · High confidence	In force	Term ends Mar 2, 2031	High confidence
US 9,402,922	Solid Composition for the Oral Administration of Dyes and Diagnostic Use Thereof In force Term ends Mar 2, 2031 · High confidence	In force	Term ends Mar 2, 2031	High confidence
US 9,402,923	Solid Composition for the Oral Administration of Dyes and Diagnostic Use Thereof In force Term ends Mar 2, 2031 · High confidence	In force	Term ends Mar 2, 2031	High confidence
US 8,895,064	Controlled Release and Taste Masking Oral Pharmaceutical Composition In force Term ends Sep 7, 2031 · High confidence	In force	Term ends Sep 7, 2031	High confidence
US 9,132,093	Controlled Release and Taste Masking Oral Pharmaceutical Composition In force Term ends Sep 7, 2031 · High confidence	In force	Term ends Sep 7, 2031	High confidence
US 9,192,581	Controlled Release and Taste Masking Oral Pharmaceutical Composition In force Term ends Sep 7, 2031 · High confidence	In force	Term ends Sep 7, 2031	High confidence
US 10,154,964	Controlled Release and Taste Masking Oral Pharmaceutical Composition In force Term ends Sep 7, 2031 · Medium confidence	In force	Term ends Sep 7, 2031	Medium confidence
US 10,172,799	Controlled Release and Taste Masking Oral Pharmaceutical Composition In force Ends no later than Sep 7, 2031 · Medium confidence	In force	Ends no later than Sep 7, 2031	Medium confidence
US 10,307,375	Controlled Release and Taste Masking Oral Pharmaceutical Composition In force Ends no later than Sep 7, 2031 · Medium confidence	In force	Ends no later than Sep 7, 2031	Medium confidence
US 10,660,858	Controlled Release and Taste Masking Oral Pharmaceutical Composition In force Term ends Sep 7, 2031 · Medium confidence	In force	Term ends Sep 7, 2031	Medium confidence

10 of 28 patents shown.

Pro members see all 28.

Pro members: see all 28 patents

Also on record, not counted in the 28: 2 patents in force now held by others · 24 patents ended · 10 applications pending · 33 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Cosmo Technologies Limited